Drug Profile
Phosphatidylzalcitabine
Latest Information Update: 14 Sep 2022
Price :
$50
*
At a glance
- Originator Vical
- Developer Fresh Tracks Therapeutics; Gilead Sciences
- Class Antivirals; Nucleosides
- Mechanism of Action RNA-directed DNA polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued HIV infections
Most Recent Events
- 07 Sep 2022 Brickell Biotech Inc is now called Fresh Tracks Therapeutics
- 31 Aug 2019 Brickell Biotech has merged with Vical to form Brickell Biotech Inc, and subsequently Brickell Biotech changed its name to Brickell Subsidiary
- 30 Jun 1999 Discontinued-Preclinical for HIV infections treatment in USA (Unknown route)